FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment

AstraZeneca just showed how fast an established cancer drug can achieve a crucial line extension.

Just two months after the pharma giant and its partners at Merck turned up at ESMO to tout some truly impressive detailed results for Lynparza as a frontline therapy for BRCA-mutated ovarian cancer, the agency has come through with a snap OK.